173 related articles for article (PubMed ID: 25012973)
1. [Proliferative vitreoretinopathy: prophylactic treatment].
Chiquet C; Rouberol F
J Fr Ophtalmol; 2014 Nov; 37(9):737-43. PubMed ID: 25012973
[TBL] [Abstract][Full Text] [Related]
2. [Proliferative vitreoretinopathy: curative treatment].
Chiquet C; Rouberol F
J Fr Ophtalmol; 2014 Oct; 37(8):653-9. PubMed ID: 24997865
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
Schaub F; Hoerster R; Schiller P; Felsch M; Kraus D; Zarrouk M; Kirchhof B; Fauser S
Trials; 2018 Jul; 19(1):384. PubMed ID: 30012187
[TBL] [Abstract][Full Text] [Related]
4. Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes.
Wickham L; Ho-Yen GO; Bunce C; Wong D; Charteris DG
Br J Ophthalmol; 2011 Sep; 95(9):1234-8. PubMed ID: 21156702
[TBL] [Abstract][Full Text] [Related]
5. Retinal Detachment and Proliferative Vitreoretinopathy.
Kwon OW; Song JH; Roh MI
Dev Ophthalmol; 2016; 55():154-62. PubMed ID: 26501375
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy].
Scheer S; Morel C; Touzeau O; Sahel JA; Laroche L
J Fr Ophtalmol; 2004 Nov; 27(9 Pt 1):1051-9. PubMed ID: 15557870
[TBL] [Abstract][Full Text] [Related]
7. [Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis].
Rouberol F; Chiquet C
J Fr Ophtalmol; 2014 Sep; 37(7):557-65. PubMed ID: 24997864
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
Charteris DG; Aylward GW; Wong D; Groenewald C; Asaria RH; Bunce C;
Ophthalmology; 2004 Dec; 111(12):2240-5. PubMed ID: 15582080
[TBL] [Abstract][Full Text] [Related]
9. Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure.
Wickham L; Bunce C; Wong D; Charteris DG
Br J Ophthalmol; 2011 Sep; 95(9):1239-44. PubMed ID: 21325394
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of proliferative vitreoretinopathy: an update.
Khan MA; Brady CJ; Kaiser RS
Retina; 2015 Feb; 35(2):165-75. PubMed ID: 25602631
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for proliferative vitreoretinopathy.
Nagasaki H; Shinagawa K; Mochizuki M
Prog Retin Eye Res; 1998 Jan; 17(1):77-98. PubMed ID: 9537796
[TBL] [Abstract][Full Text] [Related]
12. Clinical variables associated with failure of retinal detachment repair: the European vitreo-retinal society retinal detachment study report number 4.
Adelman RA; Parnes AJ; Michalewska Z; Ducournau D;
Ophthalmology; 2014 Sep; 121(9):1715-9. PubMed ID: 24766870
[TBL] [Abstract][Full Text] [Related]
13. Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin.
Kumar A; Tewari HK; Bathwal DP; Khosla PK
Indian J Ophthalmol; 1994 Mar; 42(1):31-5. PubMed ID: 7927629
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.
Tseng W; Cortez RT; Ramirez G; Stinnett S; Jaffe GJ
Am J Ophthalmol; 2004 Jun; 137(6):1105-15. PubMed ID: 15183797
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
Asaria RH; Kon CH; Bunce C; Charteris DG; Wong D; Khaw PT; Aylward GW
Ophthalmology; 2001 Jul; 108(7):1179-83. PubMed ID: 11425671
[TBL] [Abstract][Full Text] [Related]
16. Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment.
Sabatino F; Banerjee P; K Muqit MM
Surv Ophthalmol; 2024; 69(4):508-520. PubMed ID: 38492583
[TBL] [Abstract][Full Text] [Related]
17. [Postoperative proliferative vitreoretinopathy in rhegmatogenous retinal detachment associated with stage B preoperative proliferative vitreoretinopathy: comparative results of trans-scleral retinopexy with diode laser or trans-pupillary retinopexy with argon laser].
Duquesne N; Fleury J; Bonnet M
J Fr Ophtalmol; 1998 Oct; 21(8):555-9. PubMed ID: 9833220
[TBL] [Abstract][Full Text] [Related]
18. Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy.
Storey P; Alshareef R; Khuthaila M; London N; Leiby B; DeCroos C; Kaiser R;
Retina; 2014 Oct; 34(10):1945-51. PubMed ID: 24999720
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy.
Quiram PA; Gonzales CR; Hu W; Gupta A; Yoshizumi MO; Kreiger AE; Schwartz SD
Ophthalmology; 2006 Nov; 113(11):2041-7. PubMed ID: 16952397
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group.
Wiedemann P; Hilgers RD; Bauer P; Heimann K
Am J Ophthalmol; 1998 Oct; 126(4):550-9. PubMed ID: 9780100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
